Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

University of Ulsan, Ulsan College, Asan Medical Center, National Cancer Center Hospital East, The University of Osaka, Taipei Veterans General Hospital, Yonsei University Health System, Chang Gung University, Linkou Chang Gung Memorial Hospital, Aichi Cancer Center, Sungkyunkwan University, Samsung Medical Center, National Taiwan University Hospital, Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization, Korea University, China Medical University, China Medical University Hospital, Kindai University, Seoul National University Bundang Hospital, Keio University, Kyungpook National University, Japanese Foundation For Cancer Research, Seoul National University Hospital, Chiba Cancer Center, Yonsei University, Gangnam Severance Hospital, Hyogo Prefectural Cancer Center, National Cheng Kung University Hospital, National Health Research Institutes